Framingham Heart Study (FHS)-Third Generation Cohort (Gen III)
Clinical Trials URL: http://www.clinicaltrials.gov/ct...
Study Type: Epidemiology Study
Prepared on March 7, 2012
Study Dates: 2002 -
Consent: Unrestricted Consent
Commercial Use Restrictions: Yes
NHLBI Division: DCVS
Requestor's full or expedited IRB review is required for these data. Waivers are not accepted.
Collection Type: Open BioLINCC Study - See bottom of this webpage for request information
The principal objectives of the Third Generation of Framingham are to expand on identifying genetic and environmental risk factors related to the development of cardiovascular, lung, and blood diseases to three generations of Framingham Heart Study participants, and to identify determinants of risk factors, subclinical and clinical manifestations of cardiovascular, lung, and blood diseases, over the life course.
Thirty-one years after enrollment began for the second generation of the Framingham Heart Study (Framingham Offspring Study), Framingham investigators began enrolling adults with at least one parent enrolled in the Offspring study into the Framingham Generation 3 cohort. The addition of the third generation was expected to facilitate investigation of secular trends in risk factors and indicators of health and disease within families, to enhance statistical power to detect genetic and environmental determinants of complex diseases, and to clarify how subclinical cardiovascular disease predicts occurrence of overt clinical events.
4095 men and women, almost all who self reported their ethnicity as white, ages 19+ years at entry, with at least one parent in the Framingham Offspring study, participated in the study.
The children of Offspring Cohort participants were initially identified who would be 20 years of age or older by the end of the enrollment period. A higher priority for recruitment was assigned to individuals who belonged to large extended families, in order to complement phenotypic and genotypic information already obtained from prior generations. The baseline examination was begun in 2002 and completed in 2005. A second examination (2009-2011) has also been completed in the cohort.
The baseline data for the third generation of the Framingham Heart Study includes questionnaire, blood pressure, ECG, Pulmonary Function Test, and laboratory measurements as well as events reviewed and adjudicated through 2007. The cardiovascular measures under study includes: coronary heart disease (angina pectoris, myocardial infarction, coronary insufficiency and sudden and non-sudden death), stroke, hypertension, peripheral arterial disease and congestive heart failure.